GWP
NVCR icon

Gen-Wealth Partners’s NovoCure NVCR Stock Holding History

Gen-Wealth Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$288 Hold
19
– – ﹤0.01% 701
2026
Q1 		$207 Hold
19
– – ﹤0.01% 713
2025
Q4 		$246 Hold
19
– – ﹤0.01% 675
2025
Q3 		$245 Hold
19
– – ﹤0.01% 672
2025
Q2 		$338 Hold
19
– – ﹤0.01% 623
2025
Q1 		$339 Hold
19
– – ﹤0.01% 593
2024
Q4 		$566 Hold
19
– – ﹤0.01% 617
2024
Q3 		$323 Hold
19
– – ﹤0.01% 641
2024
Q2 		$325 Hold
19
– – ﹤0.01% 627
2024
Q1 		$297 Buy
+19
New +$279 ﹤0.01% 615

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Gen-Wealth Partners's NVCR Position: Q2 2026 in Review

Gen-Wealth Partners held its NovoCure (NVCR) position steady in Q2 2026 at 19 shares worth $288. The position accounts for ﹤0.01% of the portfolio, ranked #701.

Gen-Wealth Partners first reported a position in NVCR in Q1 2024 and has held it in 10 quarters since. The position peaked at $566 in Q4 2024. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Gen-Wealth Partners held 19 shares of NovoCure worth $288 as of Q2 2026.
  • Gen-Wealth Partners left its NovoCure share count unchanged in Q2 2026.
  • NovoCure made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q2 2026, its #701 holding.
  • Gen-Wealth Partners first reported a position in NovoCure in Q1 2024 and has held it in 10 quarters since.
  • Gen-Wealth Partners's NovoCure position peaked at $566 in Q4 2024.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.